Author

L. Freitas Junior

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

C. B. Moraes· 1 shared D. F. Sales-Medina· 1 shared E. L. Durigon· 1 shared G. Courtemanche· 1 shared K. R. Goncalves· 1 shared L. M. D. Romera· 1 shared L. R. P. Ferreira· 1 shared M. S. Buckeridge· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

C. B. Moraes

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

D. F. Sales-Medina, L. R. P. Ferreira, L. M. D. Romera, K. R. Goncalves, R. V. C. Guido, G. Courtemanche, M. S. Buckeridge, E. L. Durigon, C. B. Moraes, L. Freitas Junior

The paper identifies four drugs that inhibit SARS-CoV-2 in vitro infection through phenotypic screening and network analysis, providing insights for clinical repurposing.

bioRxiv · Jul 9, 2020 · PreprintMicrobiology